

NYRx Drug Class Coverage Overview: Immunomodulators – Systemic and Benlysta

NYRx Preferred Drug List

Drugs in the Immunomodulators – Systemic drug class are included on the [NYRx Preferred Drug List \(PDL\)](#) and are subject to prior authorization (PA) requirements of the [NYRx Drug Utilization Review \(DUR\) Program](#):

Preferred Drugs	Non-Preferred Drugs	Prior Authorization/Coverage Parameters
IX. Immunologic Agents		
Immunomodulators – Systemic ^{CC, ST}		
Cosentyx® Dupixent® Enbrel® Fasenra® Humira® Nucala® Xolair®	Abrilada™ (adalimumab-AFZB) Actemra® subcutaneous adalimumab-AACF (gen Idacio®) adalimumab-FKJP (gen Hulio®) adalimumab-ADAZ (gen Hyrimoz®) adalimumab-ADB (gen Cyltezo®) Adbry™ Amjevita™ Bimzelx® Cibinqo™ Cimzia® Cyltezo® (adalimumab-ADMB) Entyvio pen® Hadlima™ Hulio® (adalimumab-FKJP) Hyrimoz® (adalimumab-ADAZ) Idacio® Ilumya® Kevzara® Kineret® Olumiant® Omvoh™ pen Orenia® subcutaneous Otezla® Rinvoq™ ER Silliq™ Simponi® Skyrizi® Skyrizi® On-Body Sotyktu™ Stelara® Taltz® Tezspire® pen Tremfya® Velsipity™ Xeljanz® Xeljanz® XR Yuflyma® Yusimry™	CLINICAL CRITERIA (CC) <ul style="list-style-type: none"> Confirm diagnosis for FDA- or compendia-supported uses STEP THERAPY (ST) For indications not specified below <ul style="list-style-type: none"> Trial of a non-specific anti-inflammatory drug such as an aminosaliclylate or immunosuppressant, or a disease-modifying anti-rheumatic drug (DMARD) Trial of a TNF inhibitor prior to treatment with a JAK inhibitor INDICATION-SPECIFIC REQUIREMENTS: <ul style="list-style-type: none"> Asthma: <ul style="list-style-type: none"> history and concurrent use of a corticosteroid Nasal polyps: <ul style="list-style-type: none"> history and concurrent use of an intranasal corticosteroid Atopic dermatitis: <ul style="list-style-type: none"> Trial with a topical prescription product for a duration of at least 3 months. For JAK inhibitors: Trial of topical prescription product and systemic product for a combined duration of at least 6 months.

Prior Authorization Requirements

- Preferred drugs will not require PA if the required coverage parameters, outlined in the [PDL](#), are found in the member's Medicaid claim history at the time of pharmacy claim submission. Non-preferred drugs will require PA.
- Clinical Criteria (CC) requirements outlined in the PDL are as follows:
 - Confirmed diagnosis of FDA-approved or compendia-supported indication.
- Step Therapy (ST) requirements exist for all drugs within this drug class for indications not specified below:
 - Trial of a non-specific anti-inflammatory drug such as an amino salicylate or immunosuppressant, or a disease-modifying anti-rheumatic drug (DMARD)
 - Trial of a tumor necrosis factor (TNF) inhibitor prior to treatment with a Janus kinase (JAK) inhibitor
- Indication-specific requirements outlined in the PDL:
 - Asthma:
 - History and concurrent use of a corticosteroid
 - Nasal polyps:
 - History and concurrent use of an intranasal corticosteroid
 - Atopic dermatitis:
 - Trial with a topical prescription product for a duration of at least three months.
 - For JAK inhibitors: Trial of topical prescription product and systemic product for a combined duration of at least six months.

Benlysta® (belimumab)

Benlysta® is subject to PA requirements of the [DUR Program](#) and include confirmation of use for an FDA-approved or compendia-supported indication and trial of a DMARD prior to treatment with Benlysta.

What Pharmacy Providers Need to Do

Pharmacy providers should become familiar with the Immunomodulators – Systemic coverage criteria in the [PDL](#) and incorporate this information when discussing the need for PA with prescribers.

What Prescribers Need to Do

Prescribers should become familiar with the Immunomodulators – Systemic coverage criteria in the [PDL](#) and incorporate this information when prescribing for Medicaid members.

Resources

- [NYRx Education & Outreach Website](#)
- [NYRx Preferred Drug List](#)
- [NYRx Preferred Drug Quick List](#)
- [NYRx Prior Authorization Submission Guide](#)

Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at NYRxEO@primetherapeutics.com from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.